疼痛在转移性去势敏感性前列腺癌中的预后价值
本回顾性分析纳入意大利六家肿瘤中心的365例转移性去势敏感性前列腺癌(mCSPC)患者,评估疼痛是否为独立预后因素。34.8%的患者存在疼痛,疼痛与更高PSA、骨转移及淋巴结受累相关,且疼痛患者的总生存期(27.0 vs. 58.2个月,p<0.001)和无进展生存期(10.1 vs. 17.4个月,p<0.001)显著更短。校正CHAARTED或LATITUDE分类及其他基线预后因素后,疼痛对总生存期的负面影响仍显著。
要点
- mCSPC患者中疼痛发生率为34.8%,多与高PSA、骨转移和淋巴结受累相关。
- 疼痛患者总生存期和无进展生存期均显著缩短。
- 校正CHAARTED或LATITUDE分类后,疼痛仍是总生存期的独立不良预后因素。
核心结论
- 癌症相关疼痛在mCSPC患者中具有不良预后作用,但需前瞻性验证。
研究设计与样本
- 回顾性分析意大利六家肿瘤中心的mCSPC患者,疼痛数据可获取者共365例。
主要发现
- 疼痛组总生存期显著短于无疼痛组(27.0 vs. 58.2个月,p<0.001)。
- 疼痛组无进展生存期显著短于无疼痛组(10.1 vs. 17.4个月,p<0.001)。
- 疼痛主要与高前列腺特异性抗原值、骨转移(无论部位)及淋巴结受累相关。
- 疼痛患者多表现为高瘤负荷或高危疾病。
- 校正CHAARTED或LATITUDE分类及其他显著基线预后因素后,疼痛对总生存期的负面影响仍显著。
临床怎么用
- 在mCSPC患者评估中,应关注疼痛的存在,将其视为不良预后的提示因素。
局限性
- 回顾性分析设计,需要前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer-related pain, usually associated with bone metastases, is a frequent and debilitating morbidity in patients with prostate cancer. To date there are only limited data regarding the prognostic role of pain in men with metastatic castration-sensitive prostate cancer (mCSPC). The objective of our analysis was to assess if the presence of pain can be considered an independent prognostic factor in mCSPC patients. METHODS: A retrospective analysis was performed on patients with mCSPC referring to six oncology centers in Italy. Clinical and pathological features were recorded. Patients were considered to have pain if this was reported within the patient's file or in case of a chronic analgesic therapy was found among the concomitant medications. Survivals were estimated by the Kaplan-Meier method, and compared across groups using the log-rank test. Cox proportional hazard models, stratified according to the baseline characteristics, were used to estimate hazard ratios for overall survival (OS). All the variables were significant if p < 0.05. RESULTS: Data about pain were available for 365 cases and pain was present in 34.8% of patients. Pain was mainly associated with high value of prostate-specific antigen, metastatic bone extension regardless of the site, and lymph node involvement. mCSPC patients with pain had in most of the cases high-volume or Hr disease, and significant shorter OS (27.0 vs. 58.2 months, p < 0.001) and PFS (10.1 vs. 17.4 months, p < 0.001) compared to those without pain. The negative impact of pain on OS remained significant even if adjusted for CHAARTED or LATITUDE classification, and other significant baseline prognostic factors. CONCLUSIONS: This analysis supports the poor prognostic role of cancer-related pain in the setting of mCSPC patients. A prospective validation is required.
引用
- Iacovelli R, Ciccarese C, Caffo O, et al. The prognostic value of pain in castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32651468. doi:10.1038/s41391-020-0255-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。